Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III long-term safety and efficacy study of TAC-202 (bilastine) in allergic rhinitis
jRCT2080222571Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bilastine in perennial rhinitis and seasonal allergic rhinitis (SAR), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
bilastine
03
Conditions
perennial rhinitisseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2080222571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222571.